Table 4.
DEX-based NCs developed for drug delivery.
| DDS Type | Drug Loaded | Targeted Disease/Applications | Observations | Reference |
|---|---|---|---|---|
| NC | Camptothecin | Cancer therapies | High drug-loading rate; superior stability in aqueous solutions; notable in vitro antitumour activity against HeLa and MCF-7 cells |
[130] |
| NC | Choline kinase siRNA | siRNA cancer therapy | Successful delivery of siRNA | [131] |
| DEX-coated graphene oxide NP | Curcumin | MCF-7 breast cancer cell lines | Very good results obtained; potential DDS for chemotherapy application | [44] |
| NC | Paclitaxel and silybin | A549 lung cancer cells | Excellent encapsulation efficiency of both active substances; employs synergistic effects through chemotherapy sensitization and microenvironment modulation, improving the efficacy of cancer therapy; in vivo tests confirmed tumour growth inhibition |
[25] |
| Conjugate | Calcium ions | Calcium supplements’ carrier | Could be used as an effective carrier for new calcium supplements | [134] |
| Nanowires | Pharmaceutical applications | Useful biomaterial for medical applications | [15] | |
| NC | Cabazitaxel | Prostatic cancer | Promising DDS as a substitution for the current market formulation | [135] |
| Conjugate | Metronidazole | Protozoa infection | Very good in vivo results | [136] |